OBINUTUZUMAB, Zanubrutinib
BGB-3111-212
Phase 2 small_molecule active
Quick answer
OBINUTUZUMAB, Zanubrutinib for Relapsed/Refractory Follicular Lymphoma is a Phase 2 program (small_molecule) at BeiGene Ireland Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BeiGene Ireland Ltd
- Indication
- Relapsed/Refractory Follicular Lymphoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active